endo international plc (ENDP:NASDAQ GS)
Ivan P. Gergel M.D.
Chief Medical Officer and Senior Vice President of Drug Development, Nektar Therapeutics
|Age||Total Calculated Compensation||This person is connected to 39 board members in 3 different organizations across 6 different industries.|
See Board Relationships
Dr. Ivan P. Gergel, M.D., serves as the Chief Medical Officer and Senior Vice President of Drug Development at Nektar Therapeutics since May 19, 2014. Dr. Gergel served as the Chief Scientific Officer and Executive Vice President of Research & Development at Endo Health Solutions Inc. from April 2008 to March 31, 2014. He has been an Executive Vice President of Research & Development of Endo Pharmaceuticals Solutions Inc. since April 2008. He has full responsibility ...
Glandore Business CentresPhone: 353 1 699 4700
Dublin, Co. Dublin 2
Board Members Memberships*
Executive Vice President of Research & Development
University of Pennsylvania - The Wharton School
Royal Free and University College Medical School
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
|Michael W. Aguiar||Chief Executive Officer, President, Chief Financial Officer, Principal Accounting Officer, Senior Vice President of Finance, Treasurer and Director|
|Peter M. Hecht Ph.D.||Co-Founder, Chief Executive Officer and Director|
Ironwood Pharmaceuticals, Inc.
|James A. Schoeneck||Chief Executive Officer, President and Director|
|Peter S. Greenleaf||Chief Executive Officer, Director, Member of Commercialization Committee and Member of Science & Technology Committee|
Sucampo Pharmaceuticals, Inc.
|William J. Polvino M.D.||Chief Executive Officer and President|
Veloxis Pharmaceuticals A/S
|--||Compensation as of Fiscal Year 2013.|